AstraZeneca has unveiled a newly expanded manufacturing facility in Texas to the tune of $445m, as the drugmaker aims to meet ...
Novo Nordisk will now run a Phase III trial for Omeros' former lead asset, zaltenibart in rare blood disorder, PNH.
A consortium led by Nordic Capital and Permira has raised its bid, though certain shareholder stances remain firm.
Tubulis has completed a Series C, securing €308m ($361m) to be directed towards advancing clinical development of its ADC ...
With a legacy rooted in global scientific excellence, Sweden is quietly building one of Europe’s most dynamic biotech ...
Oceanpine Capital is to acquire an 80% equity stake in Beijing Jacoray Pharmaceutical Technology for 200m yuan ($28m).